All lobbying filings

The Nickles Group, LLC

The Nickles Group, LLC filed a Q1 report for Emergent Biosolutions on April 15, 2026, reporting $40,000 in lobbying income.

Lobbying for Emergent Biosolutions · Pharmaceutical company.

As filed: THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS.

All filings by The Nickles Group, LLC · Everything Emergent Biosolutions has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 15, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, FY2027 NDAA provisions related to biological and chemical defense and access to naloxone.

Defense

National Defense Authorization Act for FY2027, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.